Pinealon

Pinealon (also known as EDR peptide, Glu-Asp-Arg) is a prominently researched experimental compound classified strictly within the Khavinson Peptide framework. Operating primarily through advanced pharmacological pathways, its core mechanism of action is as follows: it synthetic tripeptide (Glu-Asp-Arg) bioregulatory peptide developed by Khavinson's St. Petersburg Institute. Acts as a penetrating peptide that crosses the blood-brain barrier and enters neuronal cell nuclei. Modulates gene expression in brain tissue, upregulates antioxidant enzymes (catalase, superoxide dismutase), promotes neuroprotection, and supports the pineal gland's circadian regulation. Shown to reduce hypoxia-induced neuronal damage. with an established metabolic degradation profile, In preclinical investigative trials and independent academic studies, researchers utilizing Pinealon have documented significant, quantifiable biological outcomes, primarily focusing on neuroprotection, cognitive enhancement, antioxidant, circadian rhythm support. Typical research protocols investigate administering 5000 to 10000mcg via subq pathways daily x 10 days. However, it is critically important to understand that while Pinealon demonstrates profound physiological potential in highly controlled laboratory settings, it remains classified strictly as a research chemical and has not been approved by the United States Food and Drug Administration (FDA) for human therapeutic, diagnostic, or dietary consumption. Independent chemical analysis via rigorous third-party Certificate of Analysis (COA) testing utilizing High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS) remains the industry gold standard for verifying its base elemental stability when reconstituted appropriately in sterile bacteriostatic water.